The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.
Recipient of a lung transplant.
Has confirmed CMV viremia with a viral load ≥ 1000 IU/mL and will receive or has just started SOC antiviral treatment in the past 72h as per the decision of the treating physician.
Renal failure with Creatinine clearance <15 mL/min or requiring dialysis
Severe hepatic impairment (Child-Pugh Class C)
Participating in another interventional clinical trial
Combined transplant (e.g heart-lung, lung-liver)